Compounding, Mayo Clinic and Vaccines - Pharmacy Technician Pulse

Efficiency, Education, and Evolution: What’s Next for Pharmacy Practice?

Pharmacy Times

JUNE 24, 2025

In an interview with Pharmacy Times at the 2025 Oncology Pharmacists Connect (OPC) meeting, Scott Soefje, PharmD, MBA, BCOP, director of pharmacy at Mayo Clinic, focused on the evolving role of pharmacists in healthcare, highlighting their increasing presence in outpatient settings to enhance efficiency and patient care.

Compounding Pharmacies

Compounding Pharmacies Immunization Mayo Clinic Hospitals

Pharmacist-Led Interventions Show Promise in Improving COPD Outcomes

Drug Topics

JULY 17, 2025

Mayo Clinic Staff. Mayo Clinic. ACIP Votes to Expand RSV Vaccine Recommendation to Include Adults 50 Years and Older Ashley Gallagher April 17th 2025 Article Currently, the recommendation is for patients 75 years and older and those aged 60 to 74 years with an increased risk of severe respiratory syncytial virus.

Specialty Pharmacies

Specialty Pharmacies Mayo Clinic Patient Care Compounding

Nemolizumab Shows Rapid, Sustained Efficacy in Atopic Dermatitis

Pharmacy Times

JUNE 16, 2025

Mayo Clinic. RAD 2025: Long-term data on Nemluvio® (nemolizumab) demonstrate its favorable safety profile and sustained and increased improvements in itch and skin lesions in patients with atopic dermatitis up to two years. News release. June 6, 2025. Accessed June 16, 2025. Atopic Dermatitis. News release. May 15, 2024. Ferruggia K.

Compounding Pharmacies

Compounding Pharmacies FDA Immunization Mayo Clinic

Immunotherapy Takes the Lead in Advanced Cutaneous Malignancies

Pharmacy Times

JUNE 20, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Compounding Pharmacies

Compounding Pharmacies Immunization Mayo Clinic Hospitals

Understanding Recent Changes to 505(b)(2) Drugs and Reimbursement

Pharmacy Times

JUNE 23, 2025

This act…allowed a pathway for manufacturers to create a ‘copy’ of a licensed patent product to make it cheaper and more discounted,” Soefje, director of pharmacy cancer care services and associate professor of pharmacy at Mayo Clinic in Rochester, Minnesota, said at the HOPA conference.

FDA

FDA Compounding Pharmacies Dosage Hospitals

FDA Approves Y-90 Resin Microspheres for Unrespectable Hepatocellular Carcinoma

Pharmacy Times

JULY 7, 2025

Mayo Clinic. link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. Sirtex Medical’s SIR-Spheres ® Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma. News release.

FDA

FDA Compounding Pharmacies Immunization Mayo Clinic

Pharmacists Take the Lead on Advanced Therapeutics

Pharmacy Times

JUNE 9, 2025

Tichy, PharmD, MBA, vice chair of pharmacy formulary for Mayo Clinic, explained. Still, confusion remains over the role of pharmacy and therapeutics (P&T) committees in this process. This governance issue is a very hot topic,” Eric M.

Compounding Pharmacies

Compounding Pharmacies FDA Hospitals Immunization

Donanemab-Azbt Receives FDA Label Update With New Dosing for Alzheimer Disease

Pharmacy Times

JULY 9, 2025

Mayo Clinic. FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease. Eli Lilly and Company. News release. July 9, 2025. Accessed July 9, 2025. Alzheimer’s Disease. News release. November 8, 2024. Accessed July 9, 2025. link] Gallagher A. Pharmacy Times.

Labelling

Labelling FDA Compounding Pharmacies Independent Pharmacies

Dual-Antigen Targeting in Myeloma: Improved Responses in Extramedullary Disease

Pharmacy Times

JUNE 26, 2025

In an interview with Pharmacy Times , Shaji Kumar, MD, consultant and research chair of the Division of Hematology in the Department of Internal Medicine at Mayo Clinic, discussed emerging data from the phase 2 RedirecTT-1 study (NCT04586426).

Compounding Pharmacies

Compounding Pharmacies Vaccines Immunization Mayo Clinic

TRE-5151 Receives FDA Fast Track Designation in Combination With Radiation Therapy for Prostate Cancer

Pharmacy Times

JULY 14, 2025

The treatment works by combining a targeting compound with a therapeutic radioisotope. Mayo Clinic. link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. News release. July 9, 2025. Accessed July 10, 2025. News release.

FDA

FDA Compounding Pharmacies Compounding Immunization

Belimumab Autoinjector Receives FDA Approval for Children With Active Lupus Nephritis

Pharmacy Times

JUNE 24, 2025

Mayo Clinic. link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. McGovern G. Prevalence of CKD in Patients With LN and SLE Ranges From 10% to Almost 50%, Review Finds. Pharmacy Times. February 4, 2025. Accessed June 24, 2025.

FDA

FDA Compounding Pharmacies Vaccines Immunization

FDA Approves Belimumab Autoinjection for Patients 5 and Older With Active Lupus Nephritis

Drug Topics

JUNE 24, 2025

Mayo Clinic. FDA Approves New Moderna COVID-19 Vaccine for Older Adults, High-Risk Patients Ashley Gallagher June 2nd 2025 Article The new approval is in line with recommendations that suggest booster vaccination for older adults and patients aged 12 to 64 with at least 1 or more underlying risk factors. REFERENCES 1.

FDA

FDA Immunization Vaccines Mayo Clinic

Navigating EGFR Mutations and ALK Fusions in Early-Stage Non-Small Cell Lung Cancer

Pharmacy Times

JUNE 19, 2025

1 "Immunotherapy given neoadjuvantly may not be the appropriate treatment strategy for patients with high fusion,” said Kaushal Parikh, MD, from Mayo Clinic. “In Mandatory ALK fusion testing should become part of the standard of care to better personalize treatments to a patient’s specific ALK variant.

Chemotherapy

Chemotherapy Compounding Pharmacies Hospitals Immunization

ASCO 2025: Cost-Effectiveness of Ribociclib in Early Breast Cancer

Pharmacy Times

JUNE 15, 2025

Following, HR+, HER2- early breast cancer is a common subtype where the cancer cells have estrogen and progesterone receptors but do not have excessive amounts of the HER2 protein, according to Mayo Clinic. Mayo Clinic. Clinicaltrials.gov: NCT05306340. Updated April 15, 2025. Accessed June 13, 2025. News release.

Mayo Clinic

Mayo Clinic Compounding Pharmacies Immunization Compounding

Underserved Patients Less Resilient During Pandemic Than Affluent Communities

Drug Topics

JULY 16, 2025

Mayo Clinic. McKesson Series: Using Technology to Simplify Vaccination Programs December 22nd 2020 Podcast Our latest podcast episode discusses how pharmacies can tap technology to boost vaccination programs for COVID-19 vaccines and others. Self-reported resilience during the COVID-19 pandemic. JAMA Netw Open.

Specialty Pharmacies

Specialty Pharmacies Independent Pharmacies Compounding Vaccines

Study Investigates Long-Term Cardiometabolic Impact of Early-Onset Obesity

Pharmacy Times

JULY 18, 2025

Mayo Clinic. link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. JAMA Netw Open. 2025;8(7):e2520011. doi:10.1001/jamanetworkopen.2025.20011 2025.20011 2. Long-term obesity and biological aging in young adults. EuerkAlert!

Compounding Pharmacies

Compounding Pharmacies Compounding Immunization Mayo Clinic

ASCO 2025: Promising Safety and Efficacy of Encorafenib and Binimetinib in Resected Stage II Melanoma

Pharmacy Times

JUNE 9, 2025

Mayo Clinic. Akkooi A, Mandala M, Kicinski M, Primary analysis of the EORTC-2139-MG/Columbus-AD trial: A randomized trial of adjuvant encorafenib and binimetinib versus placebo in high-risk stage II melanoma with a BRAF-V600E/K mutation. J Clin Oncol. 43, 2025 (suppl 17; abstr LBA9500). doi:10.1200/JCO.2025.43.17_suppl.LBA9500.

Compounding Pharmacies

Compounding Pharmacies Immunization Mayo Clinic Compounding

FDA Approves Expanded Labeling of Farapulse PFA System for Persistent Atrial Fibrillation

Pharmacy Times

JULY 14, 2025

Mayo Clinic. " 1 REFERENCES 1. Boston Scientific receives FDA approval for expanded labeling of FARAPULSE™ Pulsed Field Ablation System. News release. July 7, 2025. Accessed July 7, 2025. Atrial fibrillation. Accessed July 7, 2025. Boston Scientific. FARAPULSE™ Pulsed Field Ablation System. Accessed July 7, 2025.

Labelling

Labelling FDA Compounding Pharmacies Hospitals

Methylprednisolone interactions to avoid

The Checkup by Singlecare

OCTOBER 6, 2023

However, its use can result in serious adverse effects that other medications with similar side effect profiles can compound. Key takeaways: Methylprednisolone is an effective therapeutic agent to control immune responses and inflammation.

Vaccines

Vaccines Mayo Clinic FDA Immunization

Nitrofurantoin interactions to avoid

The Checkup by Singlecare

SEPTEMBER 27, 2023

Nitrofurantoin can interact with certain antacids, gout medications, anesthetics, and travel vaccines. This includes some antacids, gout medications, anesthetics, and travel vaccines, as well as methotrexate and fluconazole. This includes the oral typhoid and cholera vaccines. coli, which is a bacteria that commonly causes UTIs.

Vaccines

Vaccines Mayo Clinic Compounding Communication

Pharmacy Technician Pulse

Efficiency, Education, and Evolution: What’s Next for Pharmacy Practice?

Pharmacist-Led Interventions Show Promise in Improving COPD Outcomes

Trending Sources

Nemolizumab Shows Rapid, Sustained Efficacy in Atopic Dermatitis

Immunotherapy Takes the Lead in Advanced Cutaneous Malignancies

Understanding Recent Changes to 505(b)(2) Drugs and Reimbursement

FDA Approves Y-90 Resin Microspheres for Unrespectable Hepatocellular Carcinoma

Pharmacists Take the Lead on Advanced Therapeutics

Donanemab-Azbt Receives FDA Label Update With New Dosing for Alzheimer Disease

Dual-Antigen Targeting in Myeloma: Improved Responses in Extramedullary Disease

TRE-5151 Receives FDA Fast Track Designation in Combination With Radiation Therapy for Prostate Cancer

Belimumab Autoinjector Receives FDA Approval for Children With Active Lupus Nephritis

FDA Approves Belimumab Autoinjection for Patients 5 and Older With Active Lupus Nephritis

Navigating EGFR Mutations and ALK Fusions in Early-Stage Non-Small Cell Lung Cancer

ASCO 2025: Cost-Effectiveness of Ribociclib in Early Breast Cancer

Underserved Patients Less Resilient During Pandemic Than Affluent Communities

Study Investigates Long-Term Cardiometabolic Impact of Early-Onset Obesity

ASCO 2025: Promising Safety and Efficacy of Encorafenib and Binimetinib in Resected Stage II Melanoma

FDA Approves Expanded Labeling of Farapulse PFA System for Persistent Atrial Fibrillation

Methylprednisolone interactions to avoid

Nitrofurantoin interactions to avoid

Stay Connected